The short version of AOD9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-30 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Decaffeination is the removal of caffeine from coffee beans, cocoa, tea leaves, and other caffeine-containing materials. Decaffeinated products are commonly termed by the abbreviation decaf. To ensure product quality, manufacturers are required to test the newly decaffeinated coffee beans to make sure that caffeine concentration is relatively low. A caffeine content reduction of at least 97% is required under United States FDA standards. A 2006 study found decaffeinated drinks to contain typically 1–2% of the original caffeine content, but sometimes as much as 20%.
==== Blood tests ==== Complete blood count (CBC): a test of the white blood cells, red blood cells and platelets used to assess the presence of various disorders such as leukocytosis, leukopenia, thrombocytosis and anemia which may result from malnutrition. Chem-20: Chem-20, also known as SMA-20, is a group of twenty separate chemical tests performed on blood serum. Tests include protein and electrolytes such as potassium, chlorine and sodium, and tests specific to liver and kidney function. Glucose tolerance test: Oral glucose tolerance test (OGTT) used to assess the body's ability to metabolize glucose. Can be useful in detecting various disorders such as diabetes, an insulinoma, Cushing's Syndrome, hypoglycemia and polycystic ovary syndrome. Lipid profile: includes cholesterol (including total cholesterol, HDL and LDL) and triglycerides. Serum cholinesterase test: a test of liver enzymes (acetylcholinesterase and pseudocholinesterase) useful as a test of liver function and to assess the effects of malnutrition. Liver function tests: A series of tests used to assess liver function some of the tests are also used in the assessment of malnutrition, protein deficiency, kidney function, bleeding disorders, and Crohn's Disease. Luteinizing hormone (LH) response to gonadotropin-releasing hormone (GnRH): Tests the pituitary glands' response to GnRh, a hormone produced in the hypothalamus. Hypogonadism is often seen in anorexia nervosa cases.
On 7 April (8 April in Iran and Israel), Trump announced that he agreed to a two-week ceasefire with Iran and the proposal by Pakistan, stating that Iran would immediately open the Strait of Hormuz and work on finalizing a peace agreement. Later on the same day, Abbas Araghchi announced that Iran had agreed to the conditions. Iran claimed victory, asserting that it had forced the US to accept its 10-point plan, which includes lifting all sanctions on Iran and withdrawing all US forces from all bases in the region. Trump said the Iranian 10 point proposal was a "workable basis on which to negotiate". Hezbollah announced a pause in attacks against Israel, according to the ceasefire. Israel has also agreed to the temporary ceasefire. According to Pakistani Prime Minister Shehbaz Sharif, the ceasefire includes all fronts of the war, including Lebanon. Israeli Prime Minister Benjamin Netanyahu rejected Sharif's inclusion of Lebanon, asserting that the ceasefire "does not include Lebanon", an assertion backed by Trump and Vance. Hezbollah said that it halted attacks on Israel and on Israeli soldiers in Lebanon. A few hours later Israel launched the strongest wave of attacks on Lebanon since the start of the war. In response, Iranian media later said that Iran paused Hormuz traffic over Israeli attacks in Lebanon. The Lebanese government denounced what occurred as a war crime. The IRGC warned of a 'regretful response' if the attacks on Lebanon do not stop.
Sources: en.wikipedia.org
These are various dosage forms and technologies which include but not limited to nanoparticles, liposomes, microneedles, and hydrogels that can be used to enhance therapeutic efficacy and safety. The same route can accommodate multiple dosage forms; for example, the oral route may involve tablet, capsule, or liquid suspension. While the transdermal route may use a patch, gel, or cream. Drug delivery incorporates both of these concepts while encompassing a broader scope, including the design and engineering of systems that operate within or across these routes. Common routes of administration include oral, parenteral (injected), sublingual, topical, transdermal, nasal, ocular, rectal, and vaginal. However, modern drug delivery continue to expand the possibilities of these routes through novel and hybrid approaches. Since the approval of the first controlled-release formulation in the 1950s, research into new delivery systems has been progressing, as opposed to new drug development which has been declining. Several factors may be contributing to this shift in focus. One of the driving factors is the high cost of developing new drugs. A 2013 review found the cost of developing a delivery system was only 10% of the cost of developing a new pharmaceutical. A more recent study found the median cost of bringing a new drug to market was $985 million in 2020, but did not look at the cost of developing drug delivery systems.
One Day Interactive Session with Horse Racing officials : October 14, 2015 One Day Seminar on "Latest trends in Anti Doping Science" : October 15, 2015 3rd WADA Q/A Meeting : January 28–29, 2016 First International Conference on "Implementation of latest Guidelines in human and horse doping: Interaction between Testing authorities and Doping Control Laboratories" : November 4–5, 2016
=== On-the-way model === Roadie’s app works by connecting drivers with senders, businesses or consumers who have items that need to be delivered. Deliveries within the app are referred to as "Gigs", which Gorlin said was inspired by live music road crews, also known as roadies. A sender creates a Gig on Roadie's web app or via its API. Drivers then review deliveries in their area on their mobile app and may choose to offer to take on individual or groups of deliveries along the same route. Gigs are then assigned to drivers by Roadie's algorithm. According to the company, this model encourages drivers to choose Gigs that align with their planned schedules and routes. Roadie calls this its "on-the-way" delivery model. The go-to-market approach taken by Roadie also differs from its competitors. Rather than launching in major cities and sequentially adding new markets city-by-city, Roadie launched nationwide from its inception. The company relies on retail and airline partners to drive volume of deliveries in individual markets, which in turn builds up a network of drivers in those areas, making it easier for small businesses and consumers to send deliveries as well. This strategy allows Roadie to reach smaller cities and towns in rural or exurban communities, traditionally difficult markets for delivery providers to serve.
=== United Arab Emirates === The United Arab Emirates Armed Forces uses a European-style combat ration pack containing food and accessories for one soldier for 24 hours. Packed in the UAE using imported components, the ration box measures 245 mm × 195 mm × 115 mm and weighs 2.0 kg. Inside are 4 resealable (ziplock type) plastic bags, labeled in both Arabic & English, containing Breakfast, Lunch, Dinner, and Miscellaneous. A typical Breakfast bag has 2 foil-wrapped packages of hard brown biscuits, 1 small jar of apricot jam, a can of tuna, and an accessory pack (plastic spoon, salt, pepper, and napkin). Lunch contains a retort pouch of precooked rice, a retort pouch of chicken curry, a pouch of date pudding, and another accessory pack. Dinner has a retort pouch of pasta rigatoni, an envelope instant soup, and a third accessory pack. The Miscellaneous bag contains a small bag of hard candy, 4 packets of sugar, 4 tea bags, 2 small envelopes of milk powder, and 3 foil envelopes of instant orange juice powder. Also included are: a can of fruit, a package of ramen noodles, 2 flameless chemical ration heaters, a menu/instruction sheet, 1 pack of dried hummus powder, and a book of matches.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.